Antibodies News and Research

RSS

Penn Medicine researchers show that DNA editing errors can lead to cancer

Sometimes when the immune system makes small mistakes, the body amplifies its response in a big way: Editing errors in the DNA of developing T and B cells can cause blood cancers. Now, researchers from the Perelman School of Medicine, University of Pennsylvania have shown that when the enzyme key to cutting and pasting segments of DNA hits so-called "off-target" spots on a chromosome, the development of immune cells can lead to cancer in animal models.

11 Sep 2015

Researchers discover new strategy for attacking cancer cells

University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease.

11 Sep 2015

UVA researchers identify new strategy for attacking cancer cells

University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease. By more selectively targeting cancer cells, this method offers a strategy to reduce the length of and physical toll associated with current treatments.

10 Sep 2015

CureVac, IAVI team up to advance development, testing of AIDS vaccines

The non-profit International AIDS Vaccine Initiative (IAVI) and biopharmaceutical company CureVac are partnering to accelerate the development of AIDS vaccines, utilizing novel immunogens developed by IAVI and partners, delivered via CureVac's novel messenger RNA (mRNA) technology.

10 Sep 2015

CureVac announces official launch of U.S. operations in Cambridge, MA

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.

10 Sep 2015

New nanozyme test can help curb Ebola spread in western Africa

A new Ebola test that uses magnetic nanoparticles could help curb the spread of the disease in western Africa. Research published in Biosensors and Bioelectronics shows that the new test is 100 times more sensitive than the current test, and easier to use. Because of this, the new test makes it easier and cheaper to diagnose cases, enabling healthcare workers to isolate patients and prevent the spread of Ebola.

10 Sep 2015

Pitt scientists find faster method to identify pathogens

There are plenty of ways in the lab to determine which bug is bugging you when you're sick. The University of Pittsburgh's Xinyu Liu, Sanford Asher, and colleagues may have found a faster method.

9 Sep 2015

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

The Children's Hospital at Montefiore and the NCI-designated Albert Einstein Cancer Center today announced receipt of $1.3 million grant from the National Cancer Institute, part of the National Institutes of Health.

9 Sep 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

Researchers identify two enzymes from Legionella bacteria that are vital for protein chemistry

A research group at Umeå University in Sweden, together with researchers in Munich, have identified two enzymes from the pathogenic Legionella bacteria that are very useful in chemically modifying proteins to be used in medical drugs. The result of the study is presented in the chemical journal Angewandte Chemie International Edition.

7 Sep 2015

Familial hypercholesterolemia patients can benefit from alirocumab drug

Alirocumab lowers cholesterol in patients with heterozygous familial hypercholesterolemia to levels unreachable with statins alone, according to results from four ODYSSEY trials presented at ESC Congress today.

2 Sep 2015

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.

1 Sep 2015

Tampa General Hospital achieves Baby-Friendly hospital designation

Tampa General Hospital is the first hospital in Hillsborough County – and one of only three in the Tampa Bay area – to earn the Baby-Friendly hospital designation from Baby-Friendly USA, Inc. for its commitment to supporting breastfeeding mothers and their babies.

28 Aug 2015

Adaptive immune system plays active role in guiding development of mammary glands

In experiments with mouse tissue, UC San Francisco researchers have discovered that the adaptive immune system, generally associated with fighting bacterial and viral infections, plays an active role in guiding the normal development of mammary glands, the only organs--in female humans as well as mice--that develop predominately after birth, beginning at puberty.

28 Aug 2015

Continuous therapy improves multiple myeloma outcomes

Patients with newly diagnosed multiple myeloma receive significant progression-free and overall survival benefits from continuous treatment compared with fixed-duration therapy, suggests a pooled analysis.

27 Aug 2015

Antiviral-based therapies have potential to protect humans from deadly Ebola virus

For the first time, UK physicians have demonstrated that antiviral-based therapies have the potential to protect humans from the deadly Ebola virus. The report, published in The Lancet Infectious Diseases journal, describes a case-series of eight British health-care workers who were evacuated to the Royal Free Hospital in London, UK after possible accidental exposure to Ebola virus in Sierra Leone between January and March 2015.

26 Aug 2015

Long lasting flu vaccine using antibodies advance from TSRI and Janssen

Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots.

26 Aug 2015

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys AG and Immatics Biotechnologies GmbH announced today a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells.

26 Aug 2015

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK), efficacy, and safety of the company's recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) for on-demand treatment in patients with congenital hemophilia A or B who have developed an inhibitor to factor VIII or factor IX replacement therapy.

26 Aug 2015

TSRI, Janssen collaborate to find universal flu vaccine

Scientists from The Scripps Research Institute and the Janssen Pharmaceutical Companies of Johnson & Johnson have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots.

24 Aug 2015